on Secarna Pharmaceuticals GmbH & Co. KG
Secarna Pharmaceuticals and Curie.Bio Strengthen Collaboration
Secarna Pharmaceuticals GmbH & Co. KG has announced the expansion of its existing partnership with Curie.Bio. Initially established in May 2025, this collaboration now sees Secarna using its advanced OligoCreator® platform to assist Curie.Bio in identifying promising oligonucleotide candidates. This expanded agreement highlights the trust and productive relationship between the two companies.
Based in Martinsried, Germany, Secarna specializes in developing oligonucleotide therapeutics. Their innovative platform is known for its speed and safety in drug development. The integration with Curie.Bio's ventures aims to advance the treatment of challenging diseases, further enhancing the potential for transformative medical breakthroughs.
This strategic move is seen as a confirmation of the effective teamwork and shared goal of both organizations - to transform scientific innovation into impactful therapies. This development strengthens Secarna's pivotal role in shaping the future of medical treatments.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Secarna Pharmaceuticals GmbH & Co. KG news